CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
CSL Ltd CSL
News
CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
Mark Cuban Foundation and CSL Bring Free AI Bootcamp to Philadelphia Teens
CSL Joins Accumulus Synergy to Drive Industry Change
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
CSL Annual Profit Rises by 20% on Immunoglobulins Growth — Update
CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth
CSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season
EU Secures More Than 40 Million Bird Flu Vaccines
CSL Says 1st Half Profit Rises, Boosts Dividend — Update
CSL Says 1st Half Profit Rises, Boosts Dividend
CSL Says Cardiovascular Drug CSL112 Didn't Meet 'Efficacy Endpoint' After Study
CSL's Hemgenix Authorized by Health Canada as Gene Therapy for Hemophilia B
United States